Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior - PubMed (original) (raw)

Review

. 1994 Oct;102(4 Suppl 1):S13-24.

Affiliations

• PMID: 7942609

Review

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior

S S Bacus et al. Am J Clin Pathol. 1994 Oct.

Abstract

Transmembrane receptor tyrosine kinases that bind to growth factors transmit signals that are essential to growth and differentiation. These receptors can be classified into groups based on their structure. One group implicated in the pathogenesis of breast cancer contains receptors belonging to the erbB family. This group includes the epidermal growth factor receptors, the HER-2/neu (erbB-2), HER-3, and HER-4. Despite the structural similarity of these receptors, HER-2/neu, HER-4, and HER-3 do not bind to any ligand of the epidermal growth factor receptor. However, a 44-kD glycoprotein called neu differentiation factor (neu differentiation factor/heregulin) has been isolated. This ligand phosphorylates the HER-2/neu receptor and binds directly to HER-4 and HER-3. The abundance of erbB receptors and their ligands in breast cancers points to their functional importance in the pathogenesis and biological behavior of breast cancers. Furthermore, these receptors and ligands may hold a promise for targeted therapy for breast cancer in the future.

PubMed Disclaimer

Similar articles

• Neu and its ligands: from an oncogene to neural factors.
  Peles E, Yarden Y. Peles E, et al. Bioessays. 1993 Dec;15(12):815-24. doi: 10.1002/bies.950151207. Bioessays. 1993. PMID: 7908191 Review.
• Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
  Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Witters L, et al. Cancer Res. 2008 Sep 1;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739. Cancer Res. 2008. PMID: 18757423
• Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
  Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP. Ram TG, et al. Mol Carcinog. 1996 Mar;15(3):227-38. doi: 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E. Mol Carcinog. 1996. PMID: 8597535
• The role of the HER-2/neu oncogene in gynecologic cancers.
  Cirisano FD, Karlan BY. Cirisano FD, et al. J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. J Soc Gynecol Investig. 1996. PMID: 8796816 Review.

Cited by

• Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
  Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ. Rosemblit C, et al. Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796172 Free PMC article.
• DNA Mutations May Not Be the Cause of Cancer.
  Adjiri A. Adjiri A. Oncol Ther. 2017;5(1):85-101. doi: 10.1007/s40487-017-0047-1. Epub 2017 May 15. Oncol Ther. 2017. PMID: 28680959 Free PMC article.
• Associations of Sleep Apnea, NRG1 Polymorphisms, Alcohol Consumption, and Cerebral White Matter Hyperintensities: Analysis with Genome-Wide Association Data.
  Baik I, Seo HS, Yoon D, Kim SH, Shin C. Baik I, et al. Sleep. 2015 Jul 1;38(7):1137-43. doi: 10.5665/sleep.4830. Sleep. 2015. PMID: 25325441 Free PMC article.
• Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
  Schroeder RL, Stevens CL, Sridhar J. Schroeder RL, et al. Molecules. 2014 Sep 23;19(9):15196-212. doi: 10.3390/molecules190915196. Molecules. 2014. PMID: 25251190 Free PMC article. Review.
• A mechanistic study of tumor-targeted corrole toxicity.
  Hwang JY, Lubow J, Chu D, Ma J, Agadjanian H, Sims J, Gray HB, Gross Z, Farkas DL, Medina-Kauwe LK. Hwang JY, et al. Mol Pharm. 2011 Dec 5;8(6):2233-43. doi: 10.1021/mp200094w. Epub 2011 Oct 25. Mol Pharm. 2011. PMID: 21981771 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal